Integrated BioPharma Reports Results for Its Quarter Ended September 30, 2025
Rhea-AI Summary
Integrated BioPharma (OTCQX: INBP) reported results for the quarter ended September 30, 2025. Revenue was $12.7 million, down 6.6% from $13.6 million a year earlier. Gross profit fell to $1.02 million from $1.37 million and operating income declined to $0.16 million from $0.49 million. Net income was $0.12 million, or $0.00 diluted per share, versus $0.26 million, or $0.01 diluted, in the prior-year quarter.
The company said its two largest Contract Manufacturing customers accounted for approximately 87% of revenue in Q3 2025 (85% in Q3 2024). Weighted average diluted shares were 31.42 million in Q3 2025. The company reiterated standard forward-looking cautionary language.
Positive
- Net income of $0.12 million in Q3 2025
- Operating income remained positive at $0.16 million
Negative
- Operating income down ~66.7% year-over-year (from $0.49M to $0.16M)
- Net income down ~52.5% year-over-year (from $0.26M to $0.12M)
- Gross profit declined ~25.7% year-over-year (from $1.37M to $1.02M)
- High customer concentration: top two customers ≈87% of revenue in Q3 2025
News Market Reaction 1 Alert
On the day this news was published, INBP gained 0.32%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
HILLSIDE, NJ / ACCESS Newswire / November 10, 2025 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended September 30, 2025.
Revenue for the quarters ended September 30, 2025 was
For the quarters ended September 30, 2025 and 2024, the Company had net income of approximately
"Our revenue decreased by approximately
A summary of our financial results for the three months ended September 30, 2025 and 2024 follows:
INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
(unaudited)
Three Months Ended | ||||||||
September 30, | ||||||||
2025 | 2024 | |||||||
Total revenue | $ | 12,689 | $ | 13,617 | ||||
Cost of sales | 11,670 | 12,246 | ||||||
Gross profit | 1,019 | 1,371 | ||||||
Selling and administrative expenses | 856 | 881 | ||||||
Operating income | 163 | 490 | ||||||
Interest income, net | 33 | 14 | ||||||
Income before income taxes | 196 | 504 | ||||||
Income tax expense, net | 73 | 245 | ||||||
Net income | $ | 123 | $ | 259 | ||||
Basic net income per common share | $ | 0.00 | $ | 0.01 | ||||
Diluted net income per common share | $ | 0.00 | $ | 0.01 | ||||
Weighted average common shares outstanding -basic | 31,059,610 | 30,099,610 | ||||||
Weighted average common shares outstanding -diluted | 31,421,338 | 30,649,977 | ||||||
About Integrated BioPharma Inc. (INBP)
Integrated BioPharma, Inc. ("INBP") is engaged primarily in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. Further information is available at ir.ibiopharma.com.
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions, that, if they never materialize or prove incorrect, could cause the results of INBP to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements generally are identified by the words "expects," "anticipates," believes," intends," "estimates," "should," "would," "strategy," "plan" and similar expressions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements and are not guarantees of future performance. Such statements speak only as of the date hereof, are subject to change and should not be relied upon for investment purposes. INBP undertakes no obligation to revise or update any statements for any reasons. The risks, uncertainties and assumptions include, among others, changes in general economic and business conditions; loss of market share through competition; introduction of competing products by other companies; the timing of regulatory approval and the introduction of new products by INBP; changes in industry capacity; pressure on prices from competition or from purchasers of INBP's products; regulatory changes in the pharmaceutical manufacturing industry and nutraceutical industry; regulatory obstacles to the introduction of new technologies or products that are important to INBP; availability of qualified personnel; the loss of any significant customers or suppliers; inflation, including inflationary pressures from any tariffs, and tightened labor markets; our ability to expand our customer base and other risks and uncertainties described in the section entitled "Risk Factors" in INBP's most recent Annual Report on Form 10-K and its subsequent Quarterly Reports on Form 10-Q. Accordingly, INBP cannot give assurance that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of INBP.
Contact: Dina Masi, CFO
Integrated BioPharma, Inc.
investors@ibiopharma.com
888.319.6962
SOURCE: Integrated BioPharma, Inc.
View the original press release on ACCESS Newswire
FAQ
What were Integrated BioPharma (INBP) revenues for Q3 2025?
Did Integrated BioPharma (INBP) report a profit in Q3 2025?
How did INBP's operating income change in Q3 2025 versus Q3 2024?
How concentrated is Integrated BioPharma's customer base in Q3 2025?
How many diluted shares were outstanding for INBP in Q3 2025?
